Thursday, March 06, 2003 11:03:04 AM
NWBT - Northwest Biotherapeutics Inc (OTC BB)
News
Northwest Biotherapeutics, Inc. to Unveil New Automated System That Eliminates Hurdles to Therapeutic Vaccine Commercialization
THURSDAY, MARCH 06, 2003 7:00 AM
- PR Newswire
BOTHELL, Wash., Mar 6, 2003 /PRNewswire-FirstCall via COMTEX/ -- Northwest Biotherapeutics, Inc. (NWBT.OB) announced today that it will unveil its new automated system, DCVax-TFF, capable of isolating and purifying in less than two hours a sufficient quantity of precursor cells, monocytes, for generating dendritic cell-based therapeutic vaccines. It will also present laboratory data demonstrating the potential of the DCVax-TFF System as a catalyst for a new generation of less complicated and more cost effective dendritic cell-based therapies.
The system and data will be presented at the invitation only, Fifth Walker's Cay Colloquium on Cancer Vaccines and Immunology sponsored by the Albert B. Sabin Vaccine Institute. The Colloquium will take place, March 5-8, 2003, at Walker's Cay, a private island in the Bahamas where President Nixon made the decision to initiate Cancer Control Month in 1969, leading to his declaration of War on Cancer.
Dr. Marnix Bosch, Northwest Biotherapeutics' Vice President of Vaccine Research and Development, is scheduled to present data from the Company's continuing evaluation of its new system on March 7, 2003. Dr. Bosch states, "Our DCVax-TFF System represents an important breakthrough that overcomes many costly and complex hurdles that previously limited the commercial potential of dendritic cell-based therapies. It rapidly and reproducibly purifies in excess of 1 billion patient monocytes suitable for preparing multiple dendritic cell-based treatments in a single cost-effective procedure."
About Northwest Biotherapeutics
Northwest Biotherapeutics is a biotechnology company focused on discovering, developing and commercializing immunotherapy products that safely generate and enhance immune system responses to effectively treat cancer. The Company's strategy is to combine its expertise in dendritic cell biology, immunology and antigen discovery with its proprietary technologies to develop cancer therapies. As part of its strategy, it is further developing diagnostic and therapeutic antibodies against its proprietary cancer targets and it is continuing refinement of its next generation system for cost effectively producing high purity dendritic cells and dendritic cell precursors for potential new cancer products.
Statements made in this news release that are not historical facts are forward-looking statements. Actual results may differ materially from those projected in any forward-looking statement. Specifically, there are a number of important factors that could cause actual results to differ materially from those anticipated, such as the timely performance of third parties and the Company's recent cost-cutting initiatives and the direct and indirect consequences of those initiatives. Additional information on these and other factors, which could affect the Company's results, are included in its Securities and Exchange Commission filings. Finally, there may be other factors not mentioned above or included in the Company's SEC filings that may cause actual results to differ materially from any forward-looking statement. You should not place undue reliance on any forward-looking statements. The Company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by securities laws.
DCVax is a registered trademark of Northwest Biotherapeutics, Inc. All rights are reserved.
SOURCE Northwest Biotherapeutics, Inc.
Mary Royals, +1-202-778-1021, mroyals@apcoworldwide.com, for
Northwest Biotherapeutics, Inc.
Website
http://www.nwbio.com
Price $ $0.10
52 Week High $ $5.28
52 Week Low $ $0.06
3 Month Avg Daily Vol (Mil) 0.15
Beta N/A
Market Cap (Mil) $ 1.7
Shares Outstanding (Mil) 17
Float (Mil) 13.1
Indicated Annual Dividend $ 0.00
Dividend Yield % 0.10 N/A
P/E Ratio (TTM)
Book Value (MRQ) $ $0.37
Price/Book (MRQ) 0.27
Sales Per Share (TTM) $ $0.01
Return on Assets (TTM) % -111.79
Return on Equity (TTM) % -410.34
Cash Per Share (MRQ) $ $0.24
Current Ratio (MRQ) 2.54
Total Debt/Equity (MRQ) 0.03
News
Northwest Biotherapeutics, Inc. to Unveil New Automated System That Eliminates Hurdles to Therapeutic Vaccine Commercialization
THURSDAY, MARCH 06, 2003 7:00 AM
- PR Newswire
BOTHELL, Wash., Mar 6, 2003 /PRNewswire-FirstCall via COMTEX/ -- Northwest Biotherapeutics, Inc. (NWBT.OB) announced today that it will unveil its new automated system, DCVax-TFF, capable of isolating and purifying in less than two hours a sufficient quantity of precursor cells, monocytes, for generating dendritic cell-based therapeutic vaccines. It will also present laboratory data demonstrating the potential of the DCVax-TFF System as a catalyst for a new generation of less complicated and more cost effective dendritic cell-based therapies.
The system and data will be presented at the invitation only, Fifth Walker's Cay Colloquium on Cancer Vaccines and Immunology sponsored by the Albert B. Sabin Vaccine Institute. The Colloquium will take place, March 5-8, 2003, at Walker's Cay, a private island in the Bahamas where President Nixon made the decision to initiate Cancer Control Month in 1969, leading to his declaration of War on Cancer.
Dr. Marnix Bosch, Northwest Biotherapeutics' Vice President of Vaccine Research and Development, is scheduled to present data from the Company's continuing evaluation of its new system on March 7, 2003. Dr. Bosch states, "Our DCVax-TFF System represents an important breakthrough that overcomes many costly and complex hurdles that previously limited the commercial potential of dendritic cell-based therapies. It rapidly and reproducibly purifies in excess of 1 billion patient monocytes suitable for preparing multiple dendritic cell-based treatments in a single cost-effective procedure."
About Northwest Biotherapeutics
Northwest Biotherapeutics is a biotechnology company focused on discovering, developing and commercializing immunotherapy products that safely generate and enhance immune system responses to effectively treat cancer. The Company's strategy is to combine its expertise in dendritic cell biology, immunology and antigen discovery with its proprietary technologies to develop cancer therapies. As part of its strategy, it is further developing diagnostic and therapeutic antibodies against its proprietary cancer targets and it is continuing refinement of its next generation system for cost effectively producing high purity dendritic cells and dendritic cell precursors for potential new cancer products.
Statements made in this news release that are not historical facts are forward-looking statements. Actual results may differ materially from those projected in any forward-looking statement. Specifically, there are a number of important factors that could cause actual results to differ materially from those anticipated, such as the timely performance of third parties and the Company's recent cost-cutting initiatives and the direct and indirect consequences of those initiatives. Additional information on these and other factors, which could affect the Company's results, are included in its Securities and Exchange Commission filings. Finally, there may be other factors not mentioned above or included in the Company's SEC filings that may cause actual results to differ materially from any forward-looking statement. You should not place undue reliance on any forward-looking statements. The Company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by securities laws.
DCVax is a registered trademark of Northwest Biotherapeutics, Inc. All rights are reserved.
SOURCE Northwest Biotherapeutics, Inc.
Mary Royals, +1-202-778-1021, mroyals@apcoworldwide.com, for
Northwest Biotherapeutics, Inc.
Website
http://www.nwbio.com
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
